Premium
The associated markers and their limitations for the primary screening of HCV carriers in public health examination
Author(s) -
Miyazaki Teruo,
Honda Akira,
Ikegami Tadashi,
Hara Takashi,
Saitoh Yoshifumi,
Hirayama Takeshi,
Doy Mikio,
Matsuzaki Yasushi
Publication year - 2009
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/j.1872-034x.2009.00513.x
Subject(s) - medicine , hepatitis c virus , alanine aminotransferase , population , alanine transaminase , hepatitis c , gastroenterology , multivariate analysis , receiver operating characteristic , immunology , virus , environmental health
Aim: Although the anti‐hepatitis C virus (HCV) antibody test has been recommended to the whole Japanese population, most countries have not implemented it. The present study aims to re‐evaluate the usefulness of markers examined in the general health examination for the initial screening of HCV carriers. Methods: Of the overall population, 25 142 individuals (8876 males, 16 266 females) participated in health examinations with HCV tests in 2005, and the most commonly associated markers for HCV‐positive subjects were explored by multivariate analysis, based on blood biochemical, physical, sphygmomanometric and hematological parameters. Thereafter, the efficiencies of the markers were estimated from a total population of 85 013 individuals (29 502 males, 55 511 females) in 2003–2005. Results: The most significantly associated markers for HCV positivity were aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Optimal limits of ALT and AST by receiver–operator characteristic (ROC) analysis were 24 and 27 IU (male, 33 and 28 IU; female, 22 and 26 IU), respectively. However, one‐quarter of HCV carriers were not found to be positive using the optimal limits of aminotransferases. Conclusion: The present study confirmed the limitation of serum aminotransferase levels as markers of HCV for primary screening. Therefore, at present, an anti‐HCV antibody test is required for the efficient screening of HCV carriers in all health examinations.